Journals / Mikrobiyoloji Bülteni / 2004 / Cilt: 38 - Sayı: 4

Molecular characterization of BRO beta-lactamases of Moraxella catarrhalis strains isolated from carrier children

Taşıyıcı çocuklardan izole edilen Moraxella catarrhalis suşlarında BRO beta-laktamazların moleküler tiplendirilmesi

Pages
335–340
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a result, BRO beta-lactamase typing will guide the treatment regimen against the respiratory infections that can occur due to M.catarrhalis in carrier children.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nasopharyngeal carriage of Moraxella catarrhalis is a risk factor for upper respiratory tract infections and otitis media.
📊
Key Findings & Data:In this study, we aimed to characterize BRO beta-lactamases of M.catarrhalis strains isolated from 64 children without any symptoms of respiratory disease.
💡
Conclusion & Impact:As a result, BRO beta-lactamase typing will guide the treatment regimen against the respiratory infections that can occur due to M.catarrhalis in carrier children.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:beta-Laktamazlar · Moraxella (branhamella) catarrhalis · Taşıyıcılık

Abstract

Nasopharyngeal carriage of Moraxella catarrhalis is a risk factor for upper respiratory tract infections and otitis media. In this study, we aimed to characterize BRO beta-lactamases of M.catarrhalis strains isolated from 64 children without any symptoms of respiratory disease. Gram negative diplococci grown on selective media and which are catalase, oxidase, DNase, nitrate reduction positive, glucose, maltose, sucrose and lactose fermentation negative, were diagnosed as M.catarrhalis. Antibiotic susceptibility testing was performed by agar dilution method recommended by NCCLS. BRO beta-lactamases were differentiated by restriction enzyme analysis method. The resistance rate for ampicillin was 18.8% and all the isolates were found to be sensitive to amoxicillin-clavulanate, cefazolin, cefaclor, azithromycin and ciprofloxacin. Out of 64 M.catarrhalis isolates, 57 (89%) were found beta-lactamase positive with nitrocefin disk test (Remel, USA). The presence of BRO beta-lactamases in these 57 strains (89%) was also confirmed by restriction enzyme analysis, while 7 (11%) of them were found to be negative. Among the positive strains, 47 (73.4%) were typed as BRO-1, and 10 (15.6%) were typed as BRO-2. The characterization of BRO beta-lactamases of M.catarrhalis strains in carrier children is important since the high rate of carriage predisposes to respiratory tract infections. As a result, BRO beta-lactamase typing will guide the treatment regimen against the respiratory infections that can occur due to M.catarrhalis in carrier children.

Özet

Moraxella catarrhalis'in nazofarinkste kolonize olması üst solunum yolu enfeksiyonları (ÜSYE) ve otitis media açısından bir risk faktörüdür. Bu çalışmada, solunum yolu yakınması olmayan sağlıklı 64 çocuktan izole edilen M.catarrhalis suşlannda BRO beta-laktamazlann moleküler tanımlanması amaçlanmıştır. M.catarrhalis seçici besiyerinde üreyen Gram-negatif diplokok şeklinde olan bakterilerden katalaz, oksidaz, DNaz, nitrat redüksiyonu pozitif ve glukoz, maltoz, sükroz, laktoz fermentasyonu negatif koloniler M.catarrhalis olarak tanımlanmıştır. İzolatların antibiyotik duyarlılıkları NCCLS önerilerine göre agar dilüsyon yöntemi ile tespit edilmiştir. BRO beta-laktamazlar restriksiyon enzim analizi ile belirlenmiştir. Çalışılan izolatlarda ampisiline %18.8 direnç bulunurken, amoksisilin/klavulanat, sefazolin, sefaklor, azitromisin ve siprofloksasine direnç saptanmamıştır. M.catarrhalis izolatlarının 57'sinde (%89) nitrosefin disk testi (Remel, USA) ile beta-laktamaz pozitifliği belirlenmiştir. Bu 57 izolatta (%89) restriksiyon enzim analizi ile de BRO beta-laktamaz varlığı gösterilmiş, 7 izolat ise (%11) beta-laktamaz negatif bulunmuştur. BRO beta-laktamazlann 47'si (%73.4) BRO-1,10'u (%15.6) BRO-2 olarak tiplendirilmiştir. M.catarrhalis taşıyıcılığı yüksek olan çocuklarda bu bakteriye bağlı ÜSYE'na daha sık rastlandığı için, bu çocuklarda M.catarrhalis izolatlarının BRO beta-laktamaz karakterizasyonu önem taşımaktadır. Sonuç olarak, BRO beta-laktamazlann tanımlanması, taşıyıcı çocuklarda bu bakteriye bağlı olarak gelişebilecek solunum yolu enfeksiyonlarının tanı ve tedavisinde yol gösterici olacaktır.

🔖

Cite This Article

KÖSEOĞLU, Ö., ERGİN, A., AYDIN, G. N., HASÇELİK, G. (2004). Molecular characterization of BRO beta-lactamases of Moraxella catarrhalis strains isolated from carrier children. Mikrobiyoloji Bülteni, Cilt: 38 - Sayı: 4, 335–340. https://ajindex.com/articles/299653

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Faden H, Harabachi Y, Hong T, Wanda T. Epidemiology of Moraxella catarrhalis in children during the first 2 years of life Relationship to otitis media. J Infect Dis 1994, 169 1312-1317
  2. McGregor K, Chang BJ. Mee BJ, Riley TV: Moraxella catarrhalis: Clinical significance, antimicrobial susceptibility and BRO beta-lactamases. Eur J Clin Microbiol Infect Dis 1998, 17 219-234
  3. Greiner O, Day PJ, Altwegg M, Nadal D Quantitative detection of Moraxella catarrhalis in nasopharyngeal secretions by real-time PCR J Clin Microbiol 2003, 41:1386-1390
  4. Bootsma H J. Dijk HV. Verhoef J, Fleer A. Mooi FT Molecular characterization of the BRO beta-lactamase of Moraxella (Branhamella) catarrhalis. Antimicrob Agents Chemother 1996, 40 966-972
  5. Verduin CM, Hol C, Fleer A, Dijk H and Belkum A Morexalla catarrhalis: From emerging to established pathogen. Clin Microbiol Rev 2002, 15: 125-144 6. National Committee for Clinical Laboratory Standards Methods for dilution antibiotic susceptibility tests for bacteria that grow aerobically: Approved Standard M7-A5, 5th ed 2000 NCCLS, Wayne. Pa 7. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing Supplemental tables M100-S12, 2002. NCCLS, Wayne, Pa
  6. Plessis M. Rapid discrimination between BRO beta-lactamases from clinical isolates of Moraxella catarrhalis using restriction endonuclease analysis Diagn Microbiol Infect Dis 2001 39 65-77 9. Richter SS, Winokur PL, Brucggcmarın AB, et al: Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 US medical centers during 1994-1995 and 1997-1998. Antimicrob Agents Chemother 2000, 44: 444-446
  7. Boostma HJ, Dijk H, Vauterin R Verhoef J, Mooi FR: Genesis of BRO beta-lactamase-producing Moraxella catarrhalis: Evidence for transformation-mediated horizontal transfer. Mol Microbiol 2000, 36: 93-104
  8. Bandak SI, Turnak MR, Allen LD, et al: Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries. Eur J Clin Microbiol Infect Dis 2001, 20: 55-60
  9. Doern GV, Jones RN, Pfaller MA, Kugler K: Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the Sentry antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1999, 43: 385